Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

Date

2016

Author

Kalincik, T.
Brown, J. W.
Robertson, N.
Willis, M.
Scolding, N.
Pearson, O.
Lechner-Scott, J.

Metadata

Show full item record

Abstract

…

Source

Multiple Sclerosis Journal

Volume

22

URI

https://hdl.handle.net/20.500.12712/13186

Collections